Table 1 Study characteristics of 22 eligible studies included in the quantitative analyses.

From: Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis

Study

Country

Recruitment

Periodb

RoBc

HDx

N

Aged

% female

% SR

% ChT

% RT

2 yr

3 yr

5 yrs

Bauchet (2010)9

France

2004–2004

E

1

1

952

64

38

56

59

68

●

–

–

Chang (2005)13

US (SEER)

1988–2001

E

3

1

10,987

64

43

74

–

74

●

–

●

Iwamoto (2008)20

US (SEER)

1994–2002

E

4

1

5,909

–

55

70

7

45

○

●

○

Mathiesen (2011)24

Sweden

1996–2001

E

1

1

1,110

–

–

–

–

–

●

–

–

Nava (2014)26

Italy

1997–2010

E

1

1

1,254

–

36

91

–

–

●

●

●

Ohgaki (2004)28

Switzerland

1980–1994

E

3

0

715

61

–

–

–

–

●

●

–

Rosenthal (2006)32

Australia

1998–2000

E

2

1

473

–

–

–

–

–

●

●

●

Dubrow (2013)15

US (VA)

1997–2008

E & L

1

1

1645

–

3

74

43

73

●

●

●

Eriksson (2019)16

Sweden (Umeå)

1995–2015

E & L

1

1

571

–

38

–

–

–

○

●

●

Jung (2012)22

Korea

1999–2007

E & L

1

1

2,751

–

–

–

–

–

●

●

●

Brandes (2014)10

Italy

2001–2013

L

4

1

139

59

38

–

100

100

○

●

–

Brodbelt (2015)11

UK

2007–2011

L

1

1

10,743

57

40

80

25

–

●

–

●

Bruhn (2018)12

Sweden (Jönköping)

2001–2005

L

2

1

143

–

38

34

–

–

●

–

–

Chien (2015)14,a

Taiwan

2007–2012

L

1

1

908

–

–

–

–

–

●

–

–

Fabbro-Peray (2018)17

France

2008–2008

L

1

1

2053

64

40

59

90

90

●

–

●

Gramatzki (2016)18

Switzerland

2005–2009

L

1

1

264

61

38

81

60

70

●

●

–

Graus (2013)19

Spain

2008–2010

L

2

1

834

62

39

66

61

72

●

●

–

Johnson (2018)21

US (SEER)

2006–2012

L

1

1

12,873

–

41

61

51

75

○

●

–

Morgan (2017)25

Canada

2006–2012

L

1

1

138

61

39

83

65

87

●

–

–

Rasmussen (2018)30

Denmark

2009–2014

L

1

1

1,364

64

61

–

–

–

●

●

●

Rong (2016)31

US (SEER)

2007–2012

L

4

0

13,665

63

42

76

–

60

●

–

●

Salmaggi (2008)35

Italy (Lombardy)

2005–2005

L

3

0

349

60

36

70

100

89

●

–

–

  1. GBM glioblastoma multiforme, RoB risk of bias, HDx all cases with histological diagnosis, SR surgical resection, ChT chemotherapy, RT radiotherapy, KPS Karnofsky Performance Score, TMZ temozolomide, NOS not otherwise specified, yr years, % percentage, VA Veterans Health Administration, SEER Surveillance, Epidemiology and End Results Program, OH Ohio, CA California, NC North Carolina.
  2. aThis is a single study reporting survival data on two separate populations of GBM patients.
  3. bThis denotes the analyses in which the study contributed survival data; E = recruitment before 2005 (earlier); L = recruitment during or after 2005 (later).
  4. cRisk of bias relates to survival estimate reported in the study. Scores are based on assessment of patient selection, diagnostic certainty, handling of missing data and outcome measurement. Studies are categorized into four risk of bias groups: (1) low; (2) moderate; (3) serious; (4) critical.
  5. dMedian or mean age of cohort in years depending on which was reported in the study.
Back to article page